BioCentury
ARTICLE | Cover Story

Regeneron revisits genomics

January 23, 2014 8:00 AM UTC

Regeneron Pharmaceuticals Inc. has opened a new genetics center tasked with analyzing the genomes of at least 100,000 Geisinger Health System patients in the next 5 years. The company hopes the volume of data, diversity of the patient population and rapid validation in humanized mouse models will yield more actionable opportunities than earlier sequencing efforts.

Regeneron is the latest company to enhance in-house commitments to genomics-guided drug discovery as the cost of whole-genome sequencing falls and throughput improves. Another example is Amgen Inc.'s December 2012 acquisition of deCode genetics ehf for ...